Tags

Type your tag names separated by a space and hit enter

Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study.
Dermatology. 2003; 206(3):241-8.D

Abstract

BACKGROUND AND OBJECTIVE

The aim of this study was to evaluate the efficacy of a triphasic combination oral contraceptive (OC) containing norgestimate and ethinyl estradiol in the treatment of women with acne vulgaris.

METHODS

12 female patients were included and 10 completed the trial. Over a period of 6 months, efficacy was assessed by means of facial acne lesion counts, by an investigator's global assessment, by patients' self-assessments and by measuring epidermal moisture and skin surface lipids. In addition, a photo documentation was compiled and hormone levels were measured.

RESULTS

After 6 months of therapy, the number of acne counts improved. The success of treatment was rated positively both by the investigator and by all patients but one who did not report any changes. Skin surface lipids were significantly reduced while skin hydration showed no significant change. Testosterone and progesterone decreased, and sex-hormone-binding globulin increased, significantly.

CONCLUSION

Our data show that an OC containing norgestimate and ethinyl estradiol is a good therapeutic option for women of fertile age suffering from mild to moderate acne vulgaris.

Authors+Show Affiliations

Department of Special and Environmental Dermatology, University of Vienna, General Hospital, Vienna, Austria. paul.sator@khl.magwien.gv.atNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

12673082

Citation

Sator, P-G, et al. "Clinical Evidence of the Endocrinological Influence of a Triphasic Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol in Treating Women With Acne Vulgaris. a Pilot Study." Dermatology (Basel, Switzerland), vol. 206, no. 3, 2003, pp. 241-8.
Sator PG, Schmidt JB, Hönigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study. Dermatology. 2003;206(3):241-8.
Sator, P. G., Schmidt, J. B., & Hönigsmann, H. (2003). Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study. Dermatology (Basel, Switzerland), 206(3), 241-8.
Sator PG, Schmidt JB, Hönigsmann H. Clinical Evidence of the Endocrinological Influence of a Triphasic Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol in Treating Women With Acne Vulgaris. a Pilot Study. Dermatology. 2003;206(3):241-8. PubMed PMID: 12673082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study. AU - Sator,P-G, AU - Schmidt,J B, AU - Hönigsmann,H, PY - 2002/02/13/received PY - 2002/08/08/accepted PY - 2003/4/4/pubmed PY - 2003/9/10/medline PY - 2003/4/4/entrez SP - 241 EP - 8 JF - Dermatology (Basel, Switzerland) JO - Dermatology VL - 206 IS - 3 N2 - BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the efficacy of a triphasic combination oral contraceptive (OC) containing norgestimate and ethinyl estradiol in the treatment of women with acne vulgaris. METHODS: 12 female patients were included and 10 completed the trial. Over a period of 6 months, efficacy was assessed by means of facial acne lesion counts, by an investigator's global assessment, by patients' self-assessments and by measuring epidermal moisture and skin surface lipids. In addition, a photo documentation was compiled and hormone levels were measured. RESULTS: After 6 months of therapy, the number of acne counts improved. The success of treatment was rated positively both by the investigator and by all patients but one who did not report any changes. Skin surface lipids were significantly reduced while skin hydration showed no significant change. Testosterone and progesterone decreased, and sex-hormone-binding globulin increased, significantly. CONCLUSION: Our data show that an OC containing norgestimate and ethinyl estradiol is a good therapeutic option for women of fertile age suffering from mild to moderate acne vulgaris. SN - 1018-8665 UR - https://www.unboundmedicine.com/medline/citation/12673082/Clinical_evidence_of_the_endocrinological_influence_of_a_triphasic_oral_contraceptive_containing_norgestimate_and_ethinyl_estradiol_in_treating_women_with_acne_vulgaris__A_pilot_study_ L2 - https://www.karger.com?DOI=10.1159/000068893 DB - PRIME DP - Unbound Medicine ER -